Form 4: Provectus Biopharmaceuticals Director Acquires Convertible Promissory Note and Preferred Stock

Director Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock from Provectus Biopharmaceuticals.

Summary

• On March 21, 2024, Edward Pershing, a director of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note with a value of $25,000.
• The note can be converted into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• Pershing also acquired 8,736 shares of Series D-1 Convertible Preferred Stock, bringing his total holdings to 1,515,000 shares.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative outlook.

Future Outlook

The reporting person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the 'Note') at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock on the date which is twelve months after the issue date of the Note. The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about management's confidence in the company's prospects. The acquisition of convertible securities can be seen as a form of investment in the company's future.

Key Dates